Myasthenia gravis: Association of British Neurologists' management guidelines

Type of publication: Care, Guidelines
Disease: Myasethenia gravis, Neuromuscular junction

Authors:

Sussman J, Farrugia ME, Maddison P, Hill M, Leite MI, Hilton-Jones D


Myasthenia gravis is an autoimmune disease of the neuromuscular junction for which many therapies were developed before the era of evidence based medicine. The basic principles of treatment are well known, however, patients continue to receive suboptimal treatment as a result of which a myasthenia gravis guidelines group was established under the aegis of The Association of British Neurologists. These guidelines attempt to steer a path between evidence-based practice where available, and established best practice where evidence is unavailable. Where there is insufficient evidence or a choice of options, the guidelines invite the clinician to seek the opinion of a myasthenia expert. The guidelines support clinicians not just in using the right treatments in the right order, but in optimising the use of well-known therapeutic agents. Clinical practice can be audited against these guidelines.


Published: 15 June 2015
Journal: Practical Neurology, volume 15, issue 3, pages 199-206

doi.org/10.1136/practneurol-2015-001126

The ERNs are co-funded by the
European Union (Health Programme and CEF)

EU Commission


“EURO-NMD is one of the 24 European Reference Networks (ERNs) approved by the ERN Board of Member States. The ERNs are co-funded by the European Union (Health Programme and CEF).
For more information about the ERNs and the EU health strategy,
please visit ec.europa.eu/health/ern